<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04091230</url>
  </required_header>
  <id_info>
    <org_study_id>2018/283</org_study_id>
    <nct_id>NCT04091230</nct_id>
  </id_info>
  <brief_title>New Biopsy Needle - Evaluation of Prostate Biopsy Quality</brief_title>
  <official_title>Prospective Patient Blinded Randomized Trial Comparing Biopsy Specimen Quality in a Novel Biopsy Needle and Actuator Compared to Todays Standard Tru Cut Needle and Actuator.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Skane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Region Skane</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patient blinded randomized prospective trial evaluating prostate biopsy quality of a novel
      biopsy needle.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prostate biopsy is the golden standard for diagnose of prostate cancer. Transrectal prostate
      biopsy (TRUSbx) is the most widely used technique. Due to the transrectal path the biopsy
      needle will bring bacteria from the colon into tissue. The patent should always receive
      prophylactic antibiotics to reduce the risk of clinical infection. Infections related to
      transrectal prostate biopsy (TRUSbx) are increasing in parallel with rising antibiotic
      resistance.

      The investigators have in an ex-vivo setting previously shown a drastic reduction in
      bacterial transfer across the colon wall using a novel biopsy needle designed to minimize
      bacterial transfer. Biopsy of prostatectomy specimen using the novel needle has shown biopsy
      quality equal to the tru cut biopsy needle used today.

      This is the first human pilot aiming to evaluate if biopsy quality of the novel needle is
      equal to the reference tru cut biopsy needle in prostate biopsy.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 10, 2019</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>20 patients eligible for prostate biopsy are randomized into 2 arms (10+10 patients) using either the novel needle and actuator device or standard tru cut needle and actuator device used in the clinic today. 12 biopsies are taken from each patient. Biopsy quality is evaluated by the pathologist blinded to device used.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Patient and pathologist are unaware of which needle/device is used. TRUSbx are taken from behind the back of the patient enabling masking from the patient.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>prostate biopsy length</measure>
    <time_frame>within 21 days post biopsy</time_frame>
    <description>Length of biopsy specimen in millimeters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>prostate biopsy fragmentation</measure>
    <time_frame>within 21 days post biopsy</time_frame>
    <description>The number of sections the biopsy specimen is made of</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General appearance of biopsy assessed by pathologist</measure>
    <time_frame>within 21 days post biopsy</time_frame>
    <description>General quality of biopsy specimen on a scale from 0-3 (no biopsy, poor, good, excellent)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>patient experience / pain</measure>
    <time_frame>at the time of rectal ultrasound probe insertion, estimated to a timeframe of 5-30 seconds.</time_frame>
    <description>Visual Analog Pain Scale (VAS) rating from 0-10</description>
  </other_outcome>
  <other_outcome>
    <measure>patient experience / pain</measure>
    <time_frame>at the time of injection needle advancement and periprostatic injection of local anesthesia, estimated to a timeframe of 5-10 seconds</time_frame>
    <description>Visual Analog Pain Scale (VAS) rating from 0-10</description>
  </other_outcome>
  <other_outcome>
    <measure>patient experience / pain</measure>
    <time_frame>at the exact time of biopsy sampling, estimated to a timeframe of less than 2 seconds.</time_frame>
    <description>Visual Analog Pain Scale (VAS) rating from 0-10</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Prostate Cancer (Diagnosis)</condition>
  <arm_group>
    <arm_group_label>novel needle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TRUSbx using the 18 gauge (G) 25 centimeter(cm) novel needle with 19 millimeter (mm) sample notch and a new actuator. 12 biopsies / patient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard tru cut needle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TRUSbx using a standard tru cut biopsy needle (Mermaid Medical M-biopsy 18G 25 cm biopsy needle with a 19 mm sample notch) in a standard actuator ( Moller Medical Blue RBG-1000-10-1000). 12 biopsies/ patient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TRUSbx</intervention_name>
    <description>Trans Rectal UltraSound guided Prostate Biopsy</description>
    <arm_group_label>novel needle</arm_group_label>
    <arm_group_label>standard tru cut needle</arm_group_label>
    <other_name>prostate biopsy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible for prostate biopsy

          -  Signed informed written consent

        Exclusion Criteria:

          -  None (other than general contra indications for prostate biopsy or patient not willing
             to participate)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Prostate Biopsy</gender_description>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Linder, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsingborg Hospital</name>
      <address>
        <city>Helsingborg</city>
        <state>Scania</state>
        <zip>254 37</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 10, 2019</study_first_submitted>
  <study_first_submitted_qc>September 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2019</study_first_posted>
  <last_update_submitted>September 13, 2019</last_update_submitted>
  <last_update_submitted_qc>September 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>biopsy quality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

